The U.S. spends $413 billion annually on diabetes-related care, with diabetic patients representing a significant portion of healthcare spending. Increasing awareness of metabolic health and educating people on managing glucose levels is crucial. Dexcom offers G7 continuous glucose monitors for real-time tracking and recently introduced an over-the-counter glucose biosensor called Stelo. Stelo allows people, including those without diabetes, to monitor metabolic health and understand how food, activities, and stress impact glucose levels. This device is available for less than $100 per month and provides valuable insights into individual glucose variations. Dexcom expects $40 million in revenue from Stelo this year.
Source link
CGMs Aren’t Just for People with Diabetes Anymore, Dexcom COO Says
